Introduction and Exploration of Fulvestrant in Breast Cancer
Published Online: Sunday, June 9, 2013
For High-Definition, ClickModerator, Adam M. Brufsky, MD, PhD, introduces the panel for an in-depth discussion analyzing recent trials that explored the detection, management, and treatment of metastatic breast cancer. The expert panel includes: Sara Hurvitz, MD, Joyce O’Shaughnessy, MD, Edith A. Perez, MD, Hope S. Rugo, MD, and Andrew D. Seidman, MD.
To begin the conversation, O'Shaughnessy describes the CONFIRM trial, which compared a 250 mg dose of fulvestrant to the now approved 500 mg dose. In this trial, the larger dose of fulvestrant was shown to be superior and is now the standard of care. Additionally, the FALCON trial is comparing the now approved 500 mg dose of fulvestrant to anastrozole in the first-line for patients with advanced breast cancer.
The equivocal findings from a comparison of the 250mg dose of fulvestrant to exemestane and an evaluation of pharmacokinetics raised interests in a higher dose, Perez notes. Initially, Rugo notes, researchers had doubts about whether 250 mg was actually the maximum tolerated dose, which also led to further research and the approval of the 500 mg dose. This stresses the importance of discovering the maximum tolerated dose in clinical trials, Rugo believes.
Seidman believes the 500 mg dose is correct, especially leading into trials exploring combinations.
View More From This Discussion
Introduction to an in-depth discussion analyzing recent trials that explored the detection, management, and treatment of metastatic breast cancer. To begin this discussion, panelist analyze the phase III CONFIRM trial that studied a larger dose of fulvestrant as a treatment for metastatic breast cancer.
View Episode >>>
View Episode >>>
Sara Hurvitz, MDAssistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Edith A. Perez, MDDeputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Andrew D. Seidman, MDProfessor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.